Neoleukin Therapeutics, Inc. (NLTX)

Investigation 

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neoleukin Therapeutics, Inc. ("Neoleukin" or the "Company") (NASDAQ: NLTX). The investigation concerns whether Neoleukin and certain of its officers and/or directors have violated federal securities laws.

 

On January 8, 2021, Neoleukin announced that “on January 7, 2021, it received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug (IND) Application to begin a Phase 1 clinical program of its immunotherapeutic candidate, NL-201.”  Neoleukin disclosed that “[t]he FDA has informed Neoleukin that it needs to develop a new assay that more precisely measures the amount of protein being administered and demonstrate with this assay that dose and administration procedures will accurately deliver the intended dose of NL-201” and that “[t]he FDA also had additional requests not related to the clinical hold to be addressed by amendment of the IND.”  On this news, Neoleukin’s stock price fell $1.73 per share, or 10.96%, to close at $14.05 per share on January 8, 2021.

 

If you are aware of any facts relating to this investigation, or purchased Neoleukin shares, you can assist this investigation by visiting contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.